Home » Novartis Begins Phase II Studies of COPD Treatment
Novartis Begins Phase II Studies of COPD Treatment
Novartis has started a Phase II study of QVA149 for the treatment of chronic obstructive pulmonary disease (COPD).
The randomized, double-blind, placebo-controlled, multicenter study will determine the effect of the compound on mean 24-hour heart rate, Vectura said.
QVA149 is a combination of NVA237, a muscarinic antagonist, and indacaterol, a beta-2 agonist. NVA237 was licensed to Novartis by Sosei and Vectura in 2005, and indacaterol was discovered by Novartis and is in Phase III trials for COPD.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May